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Abstract
Background: microRNAs (miRNA) are short, endogenous transcripts that negatively regulate the expression of
specific mRNA targets. miRNAs are found both in tissues and body fluids such as plasma. A major perspective for
the use of miRNAs in the clinical setting is as diagnostic plasma markers for neoplasia. While miRNAs are abundant
in tissues, they are often scarce in plasma. For quantification of miRNA in plasma it is therefore of importance to
use a platform with high sensitivity and linear performance in the low concentration range. This motivated us to
evaluate the performance of three commonly used commercial miRNA quantification platforms: GeneChip miRNA
2.0 Array, miRCURY Ready-to-Use PCR, Human panel I+II V1.M, and TaqMan Human MicroRNA Array v3.0.
Results: Using synthetic miRNA samples and plasma RNA samples spiked with different ratios of 174 synthetic
miRNAs we assessed the performance characteristics reproducibility, recovery, specificity, sensitivity and linearity. It
was found that while the qRT-PCR based platforms were sufficiently sensitive to reproducibly detect miRNAs at the
abundance levels found in human plasma, the array based platform was not. At high miRNA levels both qRT-PCR
based platforms performed well in terms of specificity, reproducibility and recovery. At low miRNA levels, as in
plasma, the miRCURY platform showed better sensitivity and linearity than the TaqMan platform.
Conclusion: For profiling clinical samples with low miRNA abundance, such as plasma samples, the miRCURY
platform with its better sensitivity and linearity would probably be superior.
Background
microRNAs (miRNAs) are short 20-23 nucleotide long
non-coding RNAs that are widely distributed in almost
all eukaryotic organisms. They have multiple functions
however the main function is believed to be post tran-
scriptional regulation of protein levels [1,2]. While miR-
NAs are often abundant in tissues, the amount found
circulating in body fluids such as plasma and serum is
often limited. It has been reported that the total RNA
level in plasma is in the range 6-300 ng/ml [3,4] and that
the miRNA fraction constitutes only a few percent of this
[5]. The mechanisms regulating secretion of miRNA into
circulation is still unclear. Reports have shown that while
endogenous miRNAs appear stable in plasma/serum
exogenous miRNAs are not, and as a result of this it has
been suggested that endogenous circulating miRNAs are
either encapsulated in microvesicles or bound to RNA-
binding proteins in complexes, e.g. Ago2 and NPM1,
protecting them from degradation [6-8]. Detailed knowl-
edge of the biological function of circulating miRNA
does not exist, however it has been shown that vesicular
miRNAs can be transferred from cell to cell and influ-
ence the behavior of the recipient cells [9].
MicroRNAs have been reported deregulated in various
diseases. Independent studies on different tissue materials
have shown that miRNA expression profiles differ between
healthy and diseased tissue, and various lines of evidence
indicate that they have great potential as diagnostic, prog-
nostic, and predictive biomarkers [10]. It is technically
demanding to quantify mature miRNAs based on the
often low-abundance, short length of mature miRNA,
homology between miRNA species, and the inclusion of
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miRNA) and precursor miRNA (pre-miRNA) transcripts.
The latter makes it difficult to construct assays that are
specific for the mature form. Nevertheless, multiple plat-
forms for quantifying mature miRNAs exist, which are
most commonly based on either quantitative real-time
PCR (qRT-PCR) or microarrays, although alternatives
exist [11]. Common to all platforms are that a reverse
transcription step is required to convert the RNA into
cDNA prior to quantification. To date two different
approaches have been utilized for this step. In the first
approach, miRNAs are reverse transcribed individually
using miRNA-specific reverse transcription primers e.g.
stemloop primers. In the second approach, miRNAs are
first tailed with a common sequence and then reverse
transcribed using a universal primer. Subsequently, the
cDNA levels of specific miRNAs are quantified by qPCR
or microarray [11].
The qRT-PCR based platforms promise to be more
sensitive than array based miRNA quantification plat-
forms [12], and their use for analyzing samples with low
miRNA levels, such as human plasma, is increasing
[13-18]. A few reports have assessed the performance of
a number of miRNA quantifying platforms, however they
mostly focused on array based platforms and analysis of
miRNA rich samples [12,19-21]. As one of the major per-
spectives for miRNAs in the clinical setting is the use as
diagnostic markers in screening for neoplasia in body
fluids, it is very important to evaluate platform perfor-
mance at the low miRNA levels found in such samples.
This motivated us to evaluate the performance of three
commonly used commercial miRNA quantification plat-
forms: GeneChip miRNA 2.0 Array (Affymetrix), miR-
CURY Ready-to-Use PCR, Human panel I+II V1.M
(Exiqon), and TaqMan
® Human MicroRNA Array v3.0
(Applied Biosystems Inc. (ABI)). Using plasma RNAs
spiked with varying concentrations of 174 synthetic miR-
NAs we evaluated the specificity, accuracy, linearity, and
sensitivity of the platforms.
Methods
Patients/Plasma/RNA isolation
The research was conducted in accordance with the
Helsinki Declaration. Informed written consent was
obtained from all patients according to local ethical regu-
lations, and research protocols were approved by the
Central Denmark Region Committees on Biomedical
Research Ethics (J. no. 1999/4678). One milliliter of
plasma was isolated from each of seven blood samples
drawn prior to surgery from patients diagnosed with
Colorectal Cancer (CRC). The plasma was pooled and
total RNA including small RNAs, were purified according
to the protocol supplied with the miRNeasy Mini Kit
(Qiagen) with the exception that 1 μg MS2 carrier RNA
(Roche) was added to the QIAzol Lysis Reagent prior to
RNA purification in order to maximize the yield and
minimize purification efficiency variation.
Synthetic miRNA samples and plasma RNA samples
spiked with synthetic miRNAs
Two pools of 88 (pool A) and 86 (pool B) synthetic miR-
NAs with sequences corresponding to miRBase v14 were
generated (Additional file 1, Table S1). Each pool con-
tained 10
8 copies of each miRNA/μl dissolved in RNA
storage solution buffer (Ambion) supplemented with
MS2 carrier in a final concentration 10 ng/μl. These
pools were mixed in ratios 1:4 and 4:1 to formulate the
two synthetic samples #1 and #2. Synthetic sample #1
contained 0.2*10
7 copies/μlo ft h ep o o lAm i R N A sa n d
0.8*10
7 copies/μlo ft h ep o o lBm i R N A sa n dv i c ev e r s a
for the synthetic sample #2. Hence, comparison of
miRNA quantifications from the two synthetic samples
should show four-fold differences for all miRNAs.
To enable evaluation of platform performance on
complex samples the synthetic miRNAs were spiked
into two RNA aliquots from the pooled plasma RNA
preparation described above. Thereby, two novel spiked
plasma RNA samples (spiked plasma RNA #1 and #2)
having the same concentrations of the synthetic miR-
NAs as the synthetic samples were generated.
Mapping of platform assays to miRBase v14 and
identification of assays targeting the synthetic miRNAs
Complete lists of assays (including the miRBase version
used for assay design) on the GeneChip miRNA 2.0
Array (Affymetrix), the miRCURY Ready-to-Use PCR V1.
M panels (Exiqon), and the TaqMan
® Human Micro-
RNA Array v3.0 TLDA cards (ABI) were obtained from
the manufacturers. All platforms included various assays
targeting sequences that could not be mapped to miR-
Base v14 or targeted non-human sequences. These were
excluded from further analysis. In order to identify assays
targeting the synthetic miRNAs, the assay target
sequences were matched to the list of synthetic miRNAs.
This revealed that of the 174 synthetic miRNAs the Gen-
eChip platform contained matching assays for all 174, the
miRCURY platform for 143, and the TaqMan platform
for 155. In total, 125 of the synthetic miRNAs were
represented on all three platforms (Additional file 1,
Table S1).
Identification of assays targeting miRNAs with sequence
homology to one or more of the synthetic miRNAs
The assay target sequences were aligned to the sequences
of the synthetic miRNAs using a Smith-Waterman based
sequence alignment algorithm, allowing up to four mis-
matches and eight nucleotide overhangs. Consequently,
we identified assays targeting miRNAs with sequence
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alignments are supplied in Additional file 2, Table S2.
RNA input for cDNA synthesis
When cDNA for the individual platforms were generated
from the synthetic and spiked plasma RNA samples, the
sample input quantities were adjusted such that, unless
stated otherwise, the same number of synthetic miRNA
copies were added per cDNA reaction (1*10
6 and 0.25*10
6
copies for the high- and low-abundance synthetic miR-
NAs). Similarly, when cDNA was generated from the pure
plasma sample (including the no-RT control) the same
volume of plasma RNA as for the spiked-plasma RNA
samples was used (corresponding to 1/6 of the RNA
extracted from 250 μl plasma). By this approach we
enabled direct comparison of the miRNA quantities esti-
mated from the cDNAs.
Duplicate aliquots of all investigated RNA samples
were used for two separate reverse transcription reac-
tions and the products of each reaction was used in
separate qPCR amplifications. This enabled evaluation
of reproducibility, of the reverse transcription and sub-
sequent qPCR amplifications.
GeneChip assay setup
R N Aw a sl a b e l e du s i n gt h e3 D N AA r r a yD e t e c t i o nF l a s h
Tag RNA Labeling Kit (Genishere), according to manufac-
turers recommendations. First, poly(A) tailing was carried
out at 37°C for 15 min in a volume of 15 μl reaction mix,
which contains 1× Reaction Buffer, 1.5 μl 25 mM MnCl2,
1 μl 1:500 diluted ATP Mix and 1 μl PAP enzyme. Second,
FlashTag Ligation was performed at room temperature for
30 min by adding 4 μl of 5× FlashTag Ligation Mix Biotin
and 2 μl T4 DNA Ligase into the 15 μl of reaction mix.
2.5 μl of Stop Solution was added to stop the reaction.
Samples were hybridized, washed and scanned with an
Affymetrix Scanner.
miRCURY LNA™ Universal RT microRNA PCR setup
cDNA synthesis and real-time qPCR was performed using
the miRCURY LNA™ Universal RT microRNA PCR sys-
tem (Exiqon, Denmark) according to the manufacturers
instructions. In brief, the RNA were tailed with a poly(A)
sequence at their 3’end and then reverse transcribed into
cDNA using a universal poly(T) primer with a 3’end
degenerate anchor and a 5’end universal tag. The cDNA
products were subsequently diluted 125 fold and trans-
ferred to the Ready-to-use microRNA PCR Human Panels
(I + II) and quantified using SYBR green based real time
PCR and LNA enhanced miRNA specific primers. The
qPCRs were run on a 7900HT thermocycler (ABI) using
the thermal-cycling parameters recommended by Exiqon.
Raw Ct values were calculated as recommended by Exiqon
using the RQ manager software v1.2.1 (ABI) with manual
settings for threshold and baseline, i.e. all miRCURY assays
were analyzed using a ΔR nt h r e s h o l do f6 0a n db a s e l i n e
subtraction using cycles 1-14.
TaqMan
® Human MicroRNA Array Set v3.0 setup
cDNA synthesis, pre-amplification, and real-time qPCR
was performed as described in the protocol associated
with the TaqMan
® Human MicroRNA Arrays Set v3.0
(ABI). In brief, RNA was reverse transcribed using Mega-
plex RT Stemloop primers (pool A or B) and the TaqMan
miRNA reverse transcription kit. For optimal sensitivity
ABI recommends inclusion of a pre-amplification step. In
this step the product of the reverse transcription reaction
was pre-amplified using Megaplex PreAmp primers (pool
A or B) and TaqMan PreAmp Master Mix. Finally, the
pre-amplification product was diluted as indicated by the
manufacturer and loaded onto the TaqMan A or B Array.
The arrays were run using a 7900HT thermocycler (ABI).
Raw Ct values were calculated as recommended by ABI
using the RQ manager software v1.2.1 (ABI) with auto-
matic baseline and threshold settings.
Statistical analysis and sequence alignment
Variance comparison test, Poisson randomness test,
Mann-Whitney U test or Fisher’s exact test were applied
to assess differences or proportions in the obtained data
[22]. P-values < 0.05 were considered significant. Repro-
ducibility and linearity were evaluated using Pearson
correlation coefficients. The statistical analyses were car-
ried out using STATA v10.1 (Statacorp), Excel 2007
(Microsoft), or the open source R-software http://www.
r-project.org/. Sequence alignments were performed
using a Smith-Waterman based sequence alignment
algorithm [23].
Results
In a pilot study evaluating the amount of plasma RNA
input necessary to detect miRNAs we found that the
qRT-PCR based platforms (TaqMan from ABI and miR-
CURY from Exiqon) reproducibly detected miRNAs
using inputs ranging from all the RNA extracted from
250 μl plasma down to as little as 1/100 of this input
(data not shown). In order not to assess the platforms at
the brink of their sensitivity it was decided that for the
platform evaluation the input per cDNA synthesis should
be 1/6 of the RNA from 250 μl plasma. The GeneChip
miRNA 2.0 Array platform from Affymetrix repeatedly
failed to produce reliable signals at this input level (data
not shown). This was not surprising, as the total amount
of RNA isolated from 250 μl plasma was well below the
minimum requirement of 100 ng total RNA stated in the
manual for the platform. Consequently, due to the lim-
ited sensitivity the GeneChip platform was excluded
from further assessment.
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To enable assessment of specificity and recovery two syn-
thetic samples with known quantities of 174 synthetic
miRNAs were formulated. The false positive rate (false
positives/(false positives + true negatives)), which equals
1-specificity, was calculated for a range of Ct detection
thresholds. In other words it was investigated how many
assays yielded a signal at a given Ct detection threshold
despite the target miRNA not being present in the syn-
thetic sample (Figure 1A and 1B). Both platforms yielded
false positives. Consistent with the pre-amplification step
included in the TaqMan setup false positives were
detected at lower Ct values for this platform than for the
miRCURY platform in which a pre-amplification step is
not included. With the pre-amplification difference in
mind the false positive rates of the two platforms were
similar (Figure 1A and 1B). For both platforms it was
found that the number of false positives increased with
increasing detection thresholds. Noticeable, the majority
of the false positives were detected at higher Ct values
than the true positives (Figure 1C and 1D, left panels)
indicating that applying carefully chosen Ct detection
thresholds is a reasonable approach to ensure acceptable
false discovery rates. To help defining these thresholds
“no reverse transcription” controls were performed (Fig-
ure 1C and 1D, right panels). This showed that while the
TaqMan platform generally did not produce signals in a
no-RT setting, a subset of the miRCURY assays (on aver-
age 66 of the 689 assays on the platform) did so at late Ct
values (generally above cycle 38). A Ct detection thresh-
old of 38 was therefore implemented for the miRCURY
platform, corresponding to a false positive rate of ~30%
in the synthetic samples (Figure 1A). Aiming at similar
false positive rate the Ct detection threshold for the Taq-
Man platform was set to 30 (Figure 1B). If not mentioned
otherwise, these threshold cycles were used throughout
the study.
Next we reasoned that a fraction of the false positives
could be caused by assay cross-reaction associated with
the close sequence relationship between some mature
miRNAs differing with as little as a single nucleotide for
some miRNAs. To assess the impact of this issue we
examined how many of the false positives showed homol-
ogy (a nucleotide difference of 4 or less) to one of the 174
synthetic miRNAs. This analysis showed for both plat-
forms that the fraction of homology related false positives
w a sa ti t sh i g h e s ta tl o wC t ’s and gradually decreased
with increasing Ct detection thresholds. Stressing the
importance of homology as a cause of false positives, we
found that the homology related false positives were sig-
nificantly enriched (p < 0.05, Poisson randomness test)
at nearly all Ct detection thresholds for both platforms
(Figure 2). While homology causes false positives for
both platforms the extent was different, i.e. at low Ct’s
nearly all the false positives of the miRCURY platform
was attributable to homology (80-90%), whilst for the
TaqMan platform the equivalent number was only ~50-
53%. This indicates that for this platform other causes
a l s op l a yac o n s i d e r a b l er o l ei nt h ef o r m a t i o no ff a l s e
positives in the low Ct range (Figure 2). Our analysis
further demonstrated, for both platforms, that the fewer
the number of mismatches, the higher the tendency for a
homologous assay to cross-react and cause a false posi-
tive detection (Table 1).
Recovery
The synthetic samples #1 and #2 were constructed such
that they contained the exact same 174 miRNAs but in
different concentrations. For 88 of the miRNAs the num-
ber of transcript copies was four-fold lower in synthetic
sample #1 than #2 and for the remaining 86 miRNAs it
was four-fold higher. The ability of the platforms to
recover these known miRNA quantity differences was
assessed for each miRNA by calculating the difference in
Ct values between the two samples. As duplicate cDNA
syntheses and qPCR setups were performed for all samples
investigated, the reported differences were in practice cal-
culated as the difference between the averages of the
duplicates. For consistency of the recovery analysis, assays
were excluded if one or more of the measurements were
detected after the detection threshold. In order to ease
comparison of the platforms the analysis was restricted to
the 125 of the 174 synthetic miRNAs for which both plat-
forms contained assays. The recovered fold-changes of
both platforms were close to the expected +/-2 Ct (four-
fold copy number differences). In the following the miR-
NAs expected to yield +/-2 Ct differences, respectively are
reported separately. For the TaqMan platform only 109 of
the 125 assays were detected in all measurements. The
number of included assays, median, interquartile range
(iqt), and variance for the miRNAs with an expected +2Ct
difference were (56, 2.18, 0.30, 0.19) and for the miRNAs
with an expected -2 Ct difference they were (53, -1.97
0.19, 0.35). The miRCURY platform detected all 125 assays
and for the miRNAs with expected +2Ct and -2Ct differ-
ences the number of included assays, median, iqt, and var-
iance were (63, 2.03, 0.20, 0.14) and (62, -2.04, 0.29, 0.09),
respectively (Figure 3A and 3B). The median fold changes
recovered by the two platforms were not significantly dif-
ferent (p-values all > 0.65, Mann-Whitney U test). How-
ever, the variance of the recovered fold-changes was
significantly larger for the TaqMan platform than the miR-
CURY platform (p < 0.001, variance comparison test))
indicating a poorer recovery accuracy of the TaqMan plat-
form. Notably, this result was obtained even though the
analysis of the TaqMan platform included only 109 of 125
common miRNAs and the analysis of the miRCURY plat-
form included them all. The primary reason for the lower
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likely also for the larger variance of the recovered fold
changes, was individual wells amplifying poorly during
qPCR in one of the TaqMan replicates (Figure 1D left
panel and Additional file 3, Figure S1) generating outliers
often detected beyond the Ct detection threshold causing
exclusion of the assays. The basis of these poor amplifica-
tions remains unknown, but since the same assays ampli-
fied satisfactorily with other samples these outliers may be
related to the particular TaqMan arrays used for the syn-
thetic samples (Additional file 3, Figure S1).
Next, recovery performance was assessed in samples
with biological level complexity, i.e. plasma-derived RNA
with the synthetic miRNAs spiked-in. Two aliquots of
the same plasma RNA preparation were spiked with syn-
thetic samples #1 and #2, generating spiked plasma RNA
samples #1 and #2. The TaqMan and miRCURY plat-
f o r m si d e n t i f i e d9 9a n d1 1 4e n d o g e n o u sm i R N A si nt h e
non-spiked plasma, respectively (Table 2). Theoretically,
these endogenous miRNAs should not impact the plat-
forms ability to recover the expected miRNA quantity
differences between the spiked plasma samples. Our ana-
lyses also confirmed this to be the case with median
recoveries very close to the expected +/-2 Ct for both
platforms. The variances of the fold changes recovered
by the two platforms were not significantly different (p =
0.92, variance comparison test), indicating that in the
spiked plasma samples the recovery accuracy of the two
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Figure 1 Assessment of the assay specificities of the miRCURY and TaqMan platforms. Utilizing the two synthetic samples #1 and #2 with
known miRNA contents enabled us to investigate the false positive rate of the individual platforms at given Ct detection thresholds. The rates
for the individual platforms are provided in (A) miRCURY and (B) TaqMan. Clearly, the number of false positives increased with increasing Ct
detection threshold indicating that carefully chosen Ct detection thresholds could potentially reduce the number of false positives without
affecting the true positives. In order to determine the thresholds for the two platforms the raw Ct’s of the synthetic samples were compared to
no-RT controls. As illustrated by plotting the raw Ct’s for the duplicate measurements of the synthetic sample #1 and the no-RT-control for
miRCURY (C) and TaqMan (D) thresholds set at Ct = 38 and Ct = 30, respectively would dramatically reduce the number of false positives. #FP,
number of false positives.
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Figure 2 Assessment of the platforms ability to discriminate miRNAs with close sequence homology. Using the synthetic samples, with
known miRNA content, it was investigated how many of the false positives detections (miRNAs not in the sample) at a given Ct detection
threshold could be related to sequence homology to a miRNA in the sample. Plotted are the number of false positives detected in the synthetic
samples at given Ct detection thresholds and it is indicated how many of these can be related to sequence homology. (A, B) TaqMan analysis of
synthetic samples #1 and #2. (C, D) miRCURY analysis of synthetic samples #1 and #2. A Poisson randomness test was used to evaluate if the
fraction of homology related false positives at a given Ct detection threshold was significantly higher than expected. The expected fraction was
defined as the number of potential false positives (the number of assays on a given platform targeting miRNAs not present in the investigated
sample) that have sequence homology to miRNAs in the sample. As the synthetic samples #1 and #2 contain the same miRNAs (but in different
concentrations) the expected fraction is the same for the two samples. For the TaqMan platform the expected fraction is 93 out of 565 (16%)
miRNAs and for the miRCURY platform it is 102 out of 552 (18%). **p < 0.0001, *p < 0.05.
Table 1 The number of mismatches to homologous synthetic miRNAs impacts assay cross-reaction tendency¤
miRCURY TaqMan
Number of nucleotide mismatches to synthetic miRNA* 0 1 23401234
Number of assays§ 3 18 34 52 60 3 18 30 45 57
Number of false positive assays (n)# 3 17 25 38 40 2 15 22 26 33
False positive rate (false positives/number of assays) (%) 100 94 74 73 67 67 83 73 58 58
¤ A given assay can be homologous to more than one synthetic miRNA and thereby appear in more than one of the mismatch categories. This may cause the
false positive rates to be over estimated.
* 0 mismatches means that only the length differs between the synthetic miRNA and the miRNA assayed.
§Number of assays with the given number of nucleotide mismatches to a miRNA in the synthetic samples.
#An assay was scored as false positive if detected at Ct < 38 (miRCURY) or Ct < 30 (TaqMan) in one or more of the synthetic samples #1 and #2.
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Figure 3 Assessment of the capability of the platforms to recover known miRNA copy number differences. The ability of the platforms to
recover known four-fold miRNA copy number differences between samples was assessed by calculating ΔCt’s for 125 synthetic miRNAs common
to both the TaqMan and miRCURY platforms. Shown are boxplots of the ΔCt’s obtained for TaqMan (A, C) and miRCURY (B, D). Recovery was
assessed both in the synthetic samples i.e. consisting solely of synthetic miRNAs (A, B) and the plasma RNA samples spiked with synthetic miRNAs
(C, D). Separate plots were made for miRNAs that were four fold higher (ΔCt = 2) and lower (ΔCt = -2) in sample 1 compared to 2.
Table 2 Assessment of platform reproducibility, Pearson correlation of duplicate measurements§.
Sample All assays detected The 125 spike-in miRNAs for which both platforms have assays
miRCURY TaqMan miRCURY TaqMan
r (n detected) r (n detected) r (n detected) r (n detected)
Synthetic #1 0.991 (253) 0.936 (233) 0.968 (125) 0.947 (109)
Synthetic #2 0.993 (244) 0.892 (259) 0.988 (125) 0.886 (116)
Spiked plasma RNA #1 0.994 (309) 0.983 (308) 0.995 (124) 0.982 (123)
Spiked plasma RNA #2 0.992 (300) 0.989 (308) 0.990 (124) 0.989 (119)
Plasma 0.954 (114) 0.959 (99) na na
No-RT control 0.773 (8) na (0) na na
§ Calculated for all assays with Ct’s below the detection threshold (TaqMan Ct = 30, miRCURY Ct = 38) in both duplicates.
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median, iqt, and variance for the TaqMan platform were
(62, 2.03, 3.32, 0.15) and (57, -2.03, 0.32, 0.06) and for the
miRCURY platform (62, 2.04, 0.21, 0.11) and (61, -2.13,
0.24, 0.09) (Figure 3C and 3D). It is noticeable that the
number of included TaqMan assays in this analysis nearly
reached the level of miRCURY assays (119 vs. 123 out
125 assays) indicating that the outliers observed for the
TaqMan platform with the synthetic samples were due to
the specific LDA cards used rather than general poor
performance of the platform.
Having revealed that both platforms have difficulties
recovering the expected fold change for a small subset of
miRNAs we speculated if these poorly recovered miRNAs
were the same for both platforms. This was assessed by
testing if the differences (observed - expected fold
change) of the two platforms were correlated. The analy-
sis found no correlations in neither the synthetic nor the
spiked plasma samples (r~0, Pearson correlation coeffi-
cient) (Additional file 3, Figure S2), indicating that the
problematic miRNAs are different for the two platforms.
Altogether, the recovery assessment indicates that the
majority of the assays on both platforms are capable of
detecting four-fold copy number differences and that the
miRCURY platform appears to perform slightly better
than the TaqMan platform. Further experiments are
needed to evaluate if recovery is equally good at fold
changes less than four-fold, however this is beyond the
scope of the present study.
Reproducibility
Many processing steps, each potentially introducing varia-
tion, are required to quantify miRNA transcript levels in
biological samples, including plasma. To enable evaluation
of reproducibility duplicate aliquots of all investigated
RNA samples were used for two separate reverse tran-
scription reactions and the products of each reaction was
used in separate qPCR amplifications. A total of five RNA
samples were investigated: synthetic RNA samples #1 and
#2, spiked plasma RNA samples #1 and #2 and pure
plasma RNA. The comparison of every duplicate pairs
demonstrated median Pearson correlation coefficients of
0.985 and 0.952 for the miRCURY and TaqMan platforms,
respectively (Table 2). As already mentioned, a few outlier
assays with low reproducibility were observed for the Taq-
Man platform in the analysis of the synthetic samples
(Additional file 3, Figure S1). Since the assays performed
otherwise successfully this may relate to the specific LDA
cards used for the synthetic samples rather than to the
assays themselves. To facilitate comparison of the repro-
ducibility measures for the two platforms, the analysis was
repeated and this time restricted to the 125 spike-in miR-
NAs for which assays were present on both platforms. The
same pattern was observed indicating that data produced
by the miRCURY platform was slightly more reproducible
than the TaqMan platform (Table 2).
Sensitivity and linearity
To enable assessment of sensitivity and linearity of the
platforms, a five point 10-fold dilution series of spiked
plasma RNA sample #1 were generated. For the miRCURY
platform this translates to 5000/20000 (pool A/pool B
miRNAs), 500/2000, 50/200, 5/20, and 0.5/2 template
copies added per final PCR amplification at each of the
five dilution points assuming that all the pre-PCR steps
applied were 100% efficient. Even though the same RNA
inputs were also used for the TaqMan cDNA syntheses,
similar estimates of the input copy numbers for the final
PCRs cannot be calculated as the TaqMan cDNA was pre-
amplified.
Like for the other samples investigated in this study
duplicate aliquots of each dilution point were used for two
separate reverse transcription reactions and qPCR amplifi-
cations. This enabled analysis of how decreasing input
material impacted reproducibility. In order to ease inter-
platform comparison, the analysis was again restricted to
the 125 miRNAs assayed by both platforms. As expected,
the number of detected miRNAs and the reproducibility
of the measurements decreased with increasing dilution
for both platforms (Table 3). Neither of the platforms
were sensitive enough to reproducibly detect miRNAs at
the final dilution point (0.5/2 template copies per PCR
amplification) (Table 3). At the dilution points with the
largest input concentrations the platforms performed simi-
larly, but at the dilution points with 5/20 and 50/200
template copies per PCR amplification the sensitivity of
the TaqMan platform decreased significantly (p ≤ 0.001,
Fishers Exact test) compared to the miRCURY platform
(Table 3). At 5/20 template copies per PCR amplification
the miRCURY platform detected 74% (93/125) of the miR-
NAs, while the TaqMan platform only 47% (59/125).
Noticeably, the reproducibility of the miRCURY platform
remained at the same level as the TaqMan platform
despite detecting 50% more miRNAs.
As noticed during the analysis of the synthetic samples,
the TaqMan platform had a few outliers (n = 5) in the
duplicate measurements in the second dilution point.
Again, these appeared to be caused by a few individual
wells in one of the LDA cards amplifying poorly (data
not shown). When these assays were excluded the Pear-
son correlation increased from 0.85 to 0.99 (Table 3),
indicating that the TaqMan platform at this input level
generates highly reproducible measurements.
Next we assessed the linearity of the platforms by cal-
culating Pearson correlations for each assay across the
dilution series. As neither of the platforms produced
acceptable measurements at the lowest input level of the
dilution series this point was excluded. For the linearity
Jensen et al. BMC Genomics 2011, 12:435
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measurements classified as “undetermined” were replaced
by the Ct threshold values 30 (TaqMan) or 38 (miR-
CURY) corresponding to background level. This replace-
ment was necessary to enable assessment of linearity
across all four dilution points for all 125 assays. The ana-
lysis showed that the number of assays with a linear per-
formance (r
2 ≥ 0.9) across the four log scales was
significantly higher for the miRCURY platform than for
the TaqMan platform (p < 0.001, Fisher’s Exact test) with
77% (96/125) of the miRCURY assays and only 48% (60/
125) of the TaqMan assays having a r
2 ≥ 0.9 (Figure 4).
Discussion
This study reports the results of an evaluation of the
performance of three commonly used commercially
available miRNA quantification platforms. The focus
was particular on performance in relation to minute
levels RNA input, i.e. in the range of what can be
extracted from 250 μl of human plasma. Consistent with
previous reports we found qRT-PCR based platforms to
have higher sensitivity than microarray based platforms
[12]. In fact in our hands the GeneChip miRNA 2.0
platform was not sensitive enough to reliably produce
signals with the plasma RNA input levels studied. We
Table 3 Assessment of sensitivity and reproducibility at different miRNA input levels, spanning five orders of
magnitude, Pearson correlation of duplicate measurements§
The 125 spike-in miRNAs for which both platforms have assays
miRCURY TaqMan
miRNA copies pr. PCR amplification r (n detected) r (n detected)
5,000/20,000 0.995 (124) 0.981 (123)
500/2,000 0.901 (124) 0.853 (121)
0.990 (116)*
50/200 0.920 (119) 0.930 (101)
5/20 0.829 (93) 0.843 (59)
0.5/2 0.228 (35) 0.249 (34)
§ Calculated for all assays detected in both duplicates.
* Calculated after removing five assays with outlier measurements in one of the duplicates.
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Figure 4 Evaluation of assay linearity at low miRNA input levels for 125 spike-in miRNAs common to the TaqMan and miRCURY
platforms. Linearity was assessed based on a four point dilution series, ranging four orders of magnitude, of the spiked plasma RNA sample #1.
For ease of platform comparison the data presented was restricted to the 125 spiked miRNAs queried by both platforms. The template input per
PCR reaction of these 125 miRNAs ranged from 5 - 5,000 template copies (n = 62) and 20-20,000 (n = 63). Each dilution point was measured in
duplicate and the linearity of each of the 125 assays was estimated by calculating the squared Pearson correlation coefficient, r
2 of these
measurements. Plotted are the obtained r
2 values for (A) the TaqMan platform and (B) the miRCURY platform. Dashed lines correspond to
number of assays with r
2 ≥ 0.9.
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qRT-PCR platforms.
Using samples with known miRNA contents we were
able to show that at abundant miRNA levels the techni-
cal reproducibility and sensitivity of these platforms was
good and comparable. However, at low miRNA levels,
particularly at 50/200 copies or below, the sensitivity of
the miRCURY platform was significantly higher than for
the TaqMan platform. Consistent with this we found
that the number of miRCURY assays with a high degree
of linearity (r
2 ≥ 0.9) across four log scales of miRNA
copies was significantly higher than for the TaqMan
platform. Our evaluation of the two platforms’ ability to
recover four-fold differences revealed that at the investi-
gated miRNA concentrations both platforms have an
acceptable recovery. However, based on the better sensi-
tivity and linearity of the miRCURY platform it is likely
that at lower miRNA concentrations the results of a
similar recovery analysis would have been in favor of
the miRCURY platform. We did not address recovery of
fold-changes less than four-fold, but expect that the per-
formance of both platforms will decline with decreasing
fold-changes.
Considering the inclusion of the reported sensitivity
improving pre-amplification step in the TaqMan protocol
it was surprising to find that at low miRNA levels the sen-
sitivity and linearity of the miRCURY platform was better
than the TaqMan platform. This could indicate that the
sensitivity boosting effect of the pre-amplification step is
less prominent than reported [24]. However, it should be
noted that other differences between the platforms also
exist, and alternatively, these could also play a role for the
better sensitivity of the miRCURY platform. For example,
for cDNA synthesis the miRCURY platform uses a univer-
sal approach with poly(A) end-tailing and oligo(dT)
primed reverse transcription, while the TaqMan approach
megaplexes > 300 miRNA specific stem-loop primers for
initiation of reverse transcription. Potentially the universal
approach may be more robust and sensitive than the
megaplexed approach. Another possibility is the inclusion
of LNAs in the miRCURY primer designs. LNAs make
assay design nearly independent of miRNA GC content
and compensates for many of the compromises one other-
wise would have to make with a short miRNA target
sequence of just ~22 nucleotides. Noticeably, It has pre-
viously been reported that inclusion of LNAs improves
both PCR specificity and sensitivity [25].
We also assessed the specificity of the platforms and
strikingly noticed that while the TaqMan platform gener-
ally showed no false positives in the no-RT control nearly
10% of the miRCURY assays were positive (even though
detected at late Ct’s, > 38). This could indicate that the
miRCURY platform is less specific than the TaqMan
platform. However, our analyses of the synthetic samples
revealed that within the operative range, i.e. from the
first detection to the detection threshold, the two plat-
forms produce nearly identical numbers and rates of false
positives (Figure 1). Hence, for practical purposes the
specificity of the two platforms appears equal. Impor-
tantly, the number of false positives produced by both
platforms increased exponentially with increasing detec-
tion thresholds. Hence, for both platforms the detection
threshold should be chosen with great care to obtain
acceptable false discovery rates when profiling biological
samples. Sequence similarity between miRNAs has been
reported to be potential cause of false positive detections
[11,26]. Consistent with this our analyses indicated that a
significant fraction of the false positives, for both plat-
forms, in particular at low Ct’sw a sr e l a t e dt os e q u e n c e
homology (Figure 2). The latter is critical as this is also
the detection range of the true positives making it practi-
cally impossible to distinguish the false from the true
positives. As expected we found an inverse relationship
between the number of nucleotide mismatches and the
likelihood of a false positive detection (Table 1). While
this was observed for both platforms the relationship was
more pronounced for the miRCURY than the TaqMan
platform. Along the same line the fraction of non-homol-
ogy related false positives was larger for the TaqMan
than the miRCURY platform (Figure 2). We do not
understand the basis of the non-homology related false
positives, but we perceive non-homology related amplifi-
cation as more unspecific than homology related. In sum-
mary, our specificity evaluations indicate that the LNA
based miRCURY platform compared to the stem-loop
based TaqMan platform performs poorer in no-RT con-
trols and slightly better, in terms of sequence specificity,
in template containing samples. With both platforms it
seems prudent to keep homology in mind when inter-
preting data from clinical samples and it may be advisa-
ble to consider carefully the likelihood of assay cross-
reaction before taking a particular miRNA further, e.g. to
in vitro studies.
We do not find it likely that the specificity issues of
qRT-PCR will ever be completely eliminated; however,
considering the ongoing technological shift to small
RNA sequencing the issue may also soon be alleviated.
The advantage of sequencing is that it is not hindered
by variability in melting temperatures, coexpression of
nearly identical miRNA family members, or post-tran-
scriptional modifications. Moreover, it enables identifi-
cation of novel miRNAs and unlike qRT-PCR the
validity of sequencing results are not sensitive to
changes in the miRNA sequences registered in miRBase.
Currently the minimal input requirements for most
small RNA liberary preparations are limiting for the use
of the technology for profiling low abundance miRNA
samples, such as human plasma. However, multiple
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ments down, and the results are promising [27]. Other
limitations include the RNA ligation and the PCR ampli-
fication steps in the library construction protocols both
of which bear inherent biases [21]. Furthermore the
tools for computational analysis of next generation
sequencing data are still in their infancy. However, the
technology has the potential to replace qRT-PCR as the
preferred tool for profiling low abundance miRNA
samples.
For now though, our data indicate that of the three
tested platforms, the miRCURY platform with its better
sensitivity and linearity in the low miRNA concentration
range should be the platform of choice for analysis of low
abundance miRNA samples. For analysis of samples with
high miRNA abundance both qRT-PCR-platforms can be
used, and probably also the GeneChip platform. However,
when choosing platform one should keep in mind the
poorly amplifying well phenomena we observed for some
samples with the TaqMan platform. It caused artificial
outlier measurements in the affected wells and while these
outliers relatively easy can be identified by replication this
approach may be prohibited by the availability of sample
material and/or funding.
Conclusion
For the analysis of samples with abundant miRNAs - as
can often readily be obtained from most tissue samples -
both the TaqMan and miRCURY platforms will most
likely yield good results. However, for studying samples
with low miRNA levels, such as plasma, our data indicate
that it probably would be beneficial to use the miRCURY
platform due to its better sensitivity and linearity in the
low miRNA concentration range. Future application of the
platforms on plasma from e.g. cancer patients will clarify
whether miRNAs form a new reproducible family of mole-
cules to be used for cancer diagnosis and follow-up.
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